Tag Archive trial

Early recall rates decline after second round of lung cancer screening

Dr. Brilliant no comments

In the United States the National Lung Cancer Screening Trial (NLST) showed that annual lung cancer screening of high-risk individuals with LDCT reduces lung cancer mortality by 20% and overall mortality by 7%. There are now multiple lung cancer screening trials ongoing throughout the world, but one concern is the high number of early repeat scans for suspicious findings that are in fact not lung cancer. …

First clinical trial on HER-2-negative breast cancer with nintedanib shows promising results

Dr. Expert no comments

According to Miguel Ángel Quintela, head of the Unit: “The drug combination of paclitaxel and nintedanib has turned out to be a complete success, given that it is proved to be safe and that the pathologic complete response [rate of complete recovery] was 50%, which doubles the response compared to patients treated with standard therapy with paclitaxel.” The trial has also included 10 HER-2-negative breast cancer patients, all of them in early stages of the disease. In light of the results, the CNIO Breast Cancer Clinical Research Unit has already launched a large-scale Phase II Clinical Trial to validate the results in a large group of patients. These results, including biomarker studies that will facilitate advances in personalised medicine, will be released by early 2015. …

First clinical trial on HER-2-negative breast cancer with nintedanib shows promising results — ScienceDaily

Dr. Expert no comments

According to Miguel Ángel Quintela, head of the Unit: “The drug combination of paclitaxel and nintedanib has turned out to be a complete success, given that it is proved to be safe and that the pathologic complete response [rate of complete recovery] was 50%, which doubles the response compared to patients treated with standard therapy with paclitaxel.” The trial has also included 10 HER-2-negative breast cancer patients, all of them in early stages of the disease. In light of the results, the CNIO Breast Cancer Clinical Research Unit has already launched a large-scale Phase II Clinical Trial to validate the results in a large group of patients. These results, including biomarker studies that will facilitate advances in personalised medicine, will be released by early 2015…

Bisphosphonates for osteoporosis not associated with reduced breast cancer risk, study suggests — ScienceDaily

Dr. Expert no comments

Some studies have suggested that bisphosphonates, which are commonly used to treat osteoporosis, may have antitumor and antimetastatic properties. Some observational studies have suggested bisphosphonates may protect women from breast cancer. The authors analyzed the relationship of postmenopausal breast cancer and bisphosphonate use by examining data from two randomized, double-blind, placebo-controlled trials. …

Drug combination may be highly effective in recurrent ovarian cancer

Dr. Brilliant no comments

The trial compared the activity of the combination of the drug olaparib, which blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs. olaparib alone. Trial results showed a near doubling of progression-free survival benefit for the combination therapy over use of the single drug alone…

Unexpected findings: ‘Promising’ drug failed to improve survival in glioblastoma — ScienceDaily

Dr. Expert no comments

source : http://www.sciencedaily.com/releases/2014/02/140228121437.htm

New drug could reduce asthma attacks by 87 percent

Dr. Brilliant no comments

An experimental drug being developed by Regeneron Pharmaceuticals Inc. and Sanofi SA showed promising results during a small, mid-stage clinical trial in treating a subset of patients with moderate to severe asthma, but some physicians cautioned that it was too early to say how effective the treatment may ultimately be. The drug, dupilumab, is considered one of Regeneron's most promising pipeline drugs and could eventually reach $750 million in annual U.S. sales if it gains U.S. approval to treat asthma, according to Barclays. Regeneron and Sanofi, which have a partnership to co-develop certain experimental drug programs, are also testing the drug to treat a type of eczema, the itchy skin condition, and have said dupilumab could eventually be applied to other allergic conditions. Results from the trial, published online Tuesday in the New England Journal of Medicine, showed that dupilumab reduced asthma attacks by 87 percent in patients taking the drug compared to those receiving a placebo. Side effects of the drug appeared to be relatively consistent with those of patients taking placebos. “It really raises the possibility that we've hit upon a fundamental pathway that's driving the allergic reaction in asthma,” said George D. Yancopoulos, Regeneron's chief scientific officer, in an interview. However, the trial was relatively small, enrolling 52 patients in each of the study's two treatment groups. An editorial accompanying the study results said the trial design, in which patients were gradually weaned off of standard therapies for asthma, did not reflect a “real world” environment. It's also unclear how large a swath of asthma patients will benefit from the drug, because only those with higher-than-normal disease-fighting white blood cells were admitted to the study, Michael E. Wechsler, director of the asthma program at National Jewish Health, a Denver-based research hospital that specializes in respiratory conditions, wrote in the editorial. Just 21 percent of patients screened for the trial met the inclusion criteria, Dr. Wechsler wrote. Asthma affects more than 24 million people in the U.S., but existing therapies are unable to control the condition for as many as 10 percent to 20 percent of patients, according to the study's authors. Click for more from The Wall Street Journal.source : http://www.foxnews.com/health/2013/05/22/new-drug-could-reduce-asthma-attacks-by-87-percent/